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Non-esterified fatty acids (NEFA) are the primary energy fuel for most tissues under 
fasting conditions. Their release into the circulation results partly from the hydrolysis of 
triacylglycerol-rich lipids under the action of lipoprotein lipase (EC 3.1.1.34; LPL). The 
circulating NEFA pool is in dynamic equilibrium with an interstitial pool, into which 
NEFA are also released from tissue triacylglycerol depots under the influence of hormone- 
sensitive lipase (EC 3.1.1.3; HSL). NEFA removal is dependent on tissue uptake for 
oxidation or re-esterification. Insulin is a potent regulator of circulating NEFA con- 
centrations through a stimulatory effect on LPL and an inhibitory effect on HSL; by 
enhancing glucose uptake and glycolysis, insulin also provides a-glycerophosphate, the 
substrate for NEFA re-esterification (Campbell et al. 1992). The net effect of systemic 
insulinization is a prompt, marked decline in circulating NEFA concentrations, which 
marks the switch of energy production from dominant fat oxidation to prevalent carbo- 
hydrate utilization. This action of insulin is impaired in patients with non-insulin-depen- 
dent diabetes (NIDDM), in whom day-long plasma NEFA levels are elevated despite 
normal plasma insulin concentrations (Golay et al. 1986~). Raised NEFA concentrations 
have also been reported in non-diabetic obese subjects (Golay et al. 1986b; Frayn et al. 
1996). 
According to the concept of substrate competition (Randle et al. 1963), the ability of 
insulin to restrain lipolysis is part of its action on glucose metabolism. By reducing fatty 
substrate availability, insulin promotes glucose transfer into target tissues by a combination 
of push (activation of membrane transport) and pull mechanisms (stimulation of glycogen 
synthesis, anaerobic glycolysis, and pyruvate oxidation; Groop & Ferrannini, 1993). Thus, 
insulin resistance in the lipolytic pathway is associated with insulin resistance of glucose 
metabolism as well as abnormal lipid metabolism (Reaven et al. 1988; Groop et al. 1991; 
McGany, 1992). 
The relative influence of obesity and insulin resistance on plasma NEFA 
concentrations has not been established, nor has the impact of physiological factors such 
as sex and age been considered. In the present work, we have assessed the relationship 
between NEFA and insulin action by retrospective analysis of the database of the European 
Group for the Study of Insulin Resistance (EGIR; Ferrannini et al. 1996). This database, 
collected at twenty-one European centres, includes data from 1146 healthy Caucasian men 
and women, ranging in age from 18 to 85 years, in whom insulin action was determined by 
the euglycaemic insulin clamp technique. This population sample is the largest so far in 
which insulin action has been measured directly. 
* For details, see Appendix. 
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MATERIALS AND METHODS 
Subjects 
Twenty-one clinical research centres in Europe (three in Finland, one in Sweden, two in 
UK, one in Denmark, four in Germany, one in Switzerland, seven in Italy, one in 
Yugoslavia and one in Greece) each contributed between twenty-one and 122 subjects. 
These centres agreed to provide their available clamp studies (whatever the original 
purpose of these studies) on the condition that the study subjects met the following criteria: 
(a) no clinical or laboratory evidence of cardiac, renal, liver, or endocrine disease, (b) a 
fasting plasma glucose concentration < 6.7 mmol/l and normal glucose tolerance by World 
Health Organization (WHO) criteria (WHO Expert Committee on Diabetes Mellitus, 
1980), (c) normal blood pressure, (d) no recent change ( 2 10 %) in body weight, and (e) no 
current medication. Of the 1146 subjects in the present series (766 men and 380 women), 
425 were recruited in northern Europe (Sweden, Finland and UK), 289 in central Europe 
(Denmark, Germany and Switzerland), and 432 in southern Europe (Italy, Serbia and 
Greece). At each centre, the protocol was reviewed and approved by the local Ethics 
Committee, and informed consent was obtained from all subjects before their participation. 
Protocol 
The minimum of information required for each subject was: age, anthropometric variables, 
fasting and steady-state (last 40 min of a 2 h clamp) plasma glucose and insulin measure- 
ments. Height was measured to the nearest 0.01m, weight to the nearest kilogram. BMI 
was calculated as the weight (kg) divided by the square of height (m). The waist: hip 
circumference ratio (WHR) was determined (in a subset of 372 men and 157 women) by 
measuring the waist circumference at the narrowest part of the torso, and the hip 
circumference in a horizontal plane at the level of the maximal extension of the buttocks. 
Insulin action was measured in all subjects by the euglycaemic insulin clamp technique 
(DeFronzo et al. 1979) using an insulin infusion rate of 1 mU/min per kg (6 pmol/min per 
kg). Briefly, polyethylene cannulas were inserted into an antecubital vein (for the infusion 
of glucose and insulin) and retrogradely into a wrist vein heated at 60" in a hot box or a 
heating pad (for intermittent blood sampling of arterialized venous blood). At time zero, a 
primed constant infusion of regular insulin was begun, and continued for 120 min. At 4 min 
into the insulin infusion, an exogenous glucose infusion was started, and adjusted every 5- 
10 min in order to maintain plasma glucose within approximately 10% of its baseline 
value. Blood samples were obtained at timed intervals in the fasting state and during the 
clamp, for the measurement of plasma glucose, insulin and NEFA levels. The latter were 
measured in a subset of 347 men and 160 women. In this subgroup, WHR was available for 
164 men and fifty-nine women. 
Analytical procedures 
Plasma glucose was measured by the glucose oxidase (EC 1.1.3.4) method. Plasma insulin 
concentrations were measured by radioimmunoassay. Plasma NEFA were assayed 
spectrophotometrically . 
Data analysis 
Insulin action was expressed as the whole-body glucose disposal rate (M) during steady- 
state euglycaemic hyperinsulinaemia. With the insulin dose used in the current study, 
hepatic glucose output has been previously shown to be fully suppressed in old as well as 
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young subjects (DeFronzo, 1979; Robert et al. 1982; Fink et al. 1986). Thus, M was 
calculated from the exogenous glucose infusion rate during the last 40 min of the 2 h 
clamp, after correction for changes in glucose concentration in a total distribution volume 
of 250 m1Cg (Ferrannini et al. 1985). M was normalized on a per kg fat-free mass basis 
(Ma), as calculated by Hume’s (1966) formula. Fat mass was obtained as the difference 
between body weight and fat-free mass. Fasting NEFA level was the average of two 
baseline samples, and steady-state NEFA concentration was the average of three samples 
obtained during the final 60 min of insulin infusion. 
Plasma insulin and NEFA values were log-transformed to normalize their distribution. 
Data are given as means with their standard errors. A dummy variable was introduced to 
account for between-centre differences, and was included in all regression models. The 
95 % CI were calculated for regression coefficients. 
RESULTS 
The clinical and metabolic variables of the study group are given in Tables 1 and 2. Both 
fasting and steady-state plasma NEFA levels were significantly higher in women than in 
men (P< 0.0001 for both). In univariate association, higher fasting NEFA levels were 
significantly related to increasing age and to higher BMI (or fat mass), but were not related 
to fasting plasma glucose or insulin concentrations. Higher fasting NEFA were also related 
to insulin insensitivity (Fig. 1); this relationship remained highly significant ( P <  0.0001) in 
a multiple-regression model adjusting for age, sex, and BMI (13 % of the variability of 
fasting NEFA concentrations being explained). 
By defining obesity as a BMI > 25 kg/m2, and insulin resistance as the lower 10 % of 
values of the lean subgroup (Table 3), the 174 obese individuals and the 246 lean subjects 
who were insulin sensitive (i.e. had similar M, values) had comparable fasting NEFA 
concentrations. Likewise, fasting NEFA were similarly raised in obese and lean subjects 
with insulin resistance. Following euglycaemic insulin administration, circulating NEFA 
were suppressed by 84 (SE 15) % in the whole study group (P< 0.0001; Table 2). Steady- 
state NEFA concentrations were inversely related to insulin sensitivity, the regression line 
being significantly ( P c  0.0001) steeper than that between fasting NEFA and insulin 
sensitivity (Fig. 1). Thus, age-, sex-, and BMI-adjusted fasting NEFA are predicted to be 
532 pmolll (CI 481-559) in an insulin-sensitive subject (46-year-old male with a BMI of 
26 kg/m2 and an M, value of 50 pmollmin per kg), and 588 pmoM (CI 559-603) in 
his insulin-resistant counterpart (MWM 25 pmoVmin per kg), an 11 % increase. The 
Table 1. Characteristics of the study group which included subjects from twenty-one 
clinical research centres in Europe * 
(Mean values and standard deviations) 
No. of subjects .... 507 
Male (% of total) 68 
Female (% of total) 32 
Mean SD Range 
Age (years) 46 17 18-80 
BMI (kg/m2) 26.0 5.0 17.8-55.1 
Fat mass (kg) 24 9 8-82 
Waist : hip ratio 0.92 0.09 0.59-1.18 
* For details, see p. 754. 
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Table 2. Metabolic variables of the study group which included subjects from twenty-one 
clinical research centres in Europe * 
(Mean values and standard deviations) 
Mean SD Range 
Fasting plasma glucose (mmol/l) 5.1 0.5 3 . 7 6 5  
Fasting plasma insulin (pmol/l) 62 37 10-343 
Steady-state plasma insulin (prnolfl) 501 141 213-1198 
Fasting NEFA (prnol/l) 587 218 106-1652 
Steady-state NEFA (pmol/l) 93 91 15-595 
Steady-state plasma glucose (mmoV1) 5.1 0.5 3.6-7.0 
M, (pmol/min per kg) 49.7 18.0 5.2-1 18.3 
M-, whole-body glucose disposal normalized on a per kg fat-free mass (FFM) basis; NEFA, non-esterified fatty acids. 
*For details, see p. 754. 
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Fig. 1. Relationship between fasting and post-insulin plasma non-esterified acid (NEFA) concentrations in 507 healthy 
subjects from twenty-one clinical research centres in Europe (for details, see p. 754). Values are plotted on a log scale. 
FFM, fat-free mass. 
corresponding predictions for steady-state NEFA levels are 67 pmoM (CI 55-86) and 105 
pmoM (CI 95-1 19) respectively, a 57 % increase. In univariate analysis, insulin-induced 
suppression of fasting NEFA levels was positively related to age, female gender and insulin 
sensitivity (Fig. 2), and negatively related to BMI. By multiple regression, better 
suppression of NEFA continued to be reciprocally related to both BMI and insulin 
resistance, independently of one another. 
When insulin sensitivity (M-) was set as the dependent variable in a multiple- 
regression model with age, sex, BMI, and percentage suppression of NEFA levels as the 
independent variables, 16 % of the inter-individual variability of M, was explained. 
Using the regression coefficients of this model together with the ranges of MFm, BMI and 
NEFA suppression observed in the whole study group, the quantitative contribution of sex, 
BMI, and NEFA suppression to insulin sensitivity could be estimated (Fig. 3). It can be 
seen that the maximal independent contribution of NEFA inhibition to insulin-mediated 
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Table 3. Characteristics of lean and obese subgroups of the study group which included 
subjects from twenty-one clinical research centres in Europe? 
(Mean values with their standard errors) 
Statistical 
significance 
Subgroup . . . Lean Obese of effect of 2: 
Insulin sensitivity (I) . . . Sensitive Resistant Sensitive Resistant 
n . . .  246 21 174 66 
Obesity 
Mean SE Mean SE Mean SE Mean SE I (0) 1 x 0  
BMI (kg/m2) 22.6 0.1 23.2 0.4 28.7 0.3 31.9 0.8 ** * * 
Fat mass (kg) 18 0.2 19 0.8 29 0.6 36 1.5 ** * * 
FastingNEFA(kmoV1) 563 13 707 55 578 17 663 25 ** 
FPI (pmom) 47 1 67 6 65 2 110 8 ** * * 
SSPI (pmom) 451 7 495 28 538 11 594 20 ** * 
M, (pmol/min per kg) 56.8 0.9 25.8 0.9 52.0 1.2 24.7 0.7 ** 
NEFA, non-esterified fatty acids; FPI, fasting plasma insulin concentration; SSPI, steady-state plasma insulin level; 
M-, whole-body glucose disposal normalized on a per kg fat-free mass (FFM) basis. 
* P< 0.05, ** P i  0.01. 
t For details, see p. 754. 
1 Two-way ANOVA. 
100 
- 90 s? 
.- 80- 
7 0 -  
d 6 0 -  
- 
- 
- 
u) m
3 
Lu z 
50 - 
40 
Sensitive Resistant 
Fig. 2. Percentage suppression of circulating non-esterified fatty acid (NEFA) levels during a euglycaemic insulin clamp 
in insulin-sensitive and insulin-resistant men (D) and women 0. Values are means with 1 SEM represented by vertical 
bars. Mean values for insulin-resistant men and women were significantly different from those for insulin-sensitive men 
and women: *** P< 0.001. 
glucose uptake was approximately half that of BMI. The WHR was not significantly 
associated with any NEFA measure, in men or women. 
DISCUSSION 
Our study group only included individuals with normal glucose tolerance and arterial blood 
pressure. Nonetheless, biological variables characteristically related to age, such as the 
BMI, percentage fat mass, WHR, blood pressure, and plasma glucose and LDL-cholesterol 
levels, did show the expected rise with age, as previously reported (Ferrannini et al. 1996). 
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Fig. 3. Maximal contribution of gender, BMI, and percentage suppression of circulating non-esterified fatty acid 
(NEFA) levels to the observed range of insulin sensitivity (as the whole-body glucose disposal normalized on a per kg 
fat-free mass (FFM) basis) in 507 non-diabetic subjects from twenty-one clinical research centres in Europe (for details, 
see p. 754). Data were calculated from a multiple-regression model also adjusting for age and centre. 
This confirms that our cohort, although not a random sample of the general population, still 
resembled a general population. 
The first result of the present analysis is that fasting NEFA concentrations are raised in 
the presence of insulin resistance of glucose metabolism rather than in association with 
obesity per se. Thus, in obese subjects with preserved insulin sensitivity, fasting NEFA 
were similar to those of lean insulin-sensitive subjects (Table 3). This finding implies that, 
as long as glucose metabolism is normally sensitive to insulin, NEFA concentrations are 
normal in the fasting state regardless of fat mass. 
It could be argued that, in obesity, normal absolute values of fasting NEFA are 
abnormal when viewed in the context of the raised fasting plasma insulin concentrations 
(Table 3; Coppack et al. 1994). However, in the obese, the total lipolytic flux must be 
increased simply because fat mass is expanded (Table 3). In fact, when NEFA levels are 
normalized by the fat mass, thereby yielding a rough index of intrinsic lipolytic activity, 
corrected NEFA values were 35 % lower in obese than in lean individuals. The probable 
explanation for this phenomenon is that, in the lean individual, insulin resistance involves 
both glucose metabolism and lipolysis, and the compensatory hyperinsulinaemia is 
insufficient to normalize NEFA levels. In contrast, in the obese, insulin secretion is greatly 
enhanced, and the resulting hyperinsulinaemia is more than sufficient to restrain fasting 
NEFA release in the face of an enlarged fat mass and insulin resistance. An important 
corollary is that the obese non-diabetic subject compensates for any insulin resistance of 
glucose metabolism through the hyperinsulinaemia; the latter change, however, is 
maladaptive for lipolysis, resulting in reduced mobilization of triacylglycerol stores. 
With acute insulin administration, on the other hand, the ability of the hormone to 
lower circulating NEFA was reduced as a function of both sensitivity of glucose 
metabolism and obesity per se. The simplest explanation of this finding is that, while in the 
fasting state the hyperinsulinaemia associated with obesity is capable of overcoming 
insuIin resistance, the clamp conditions greatly reduce this compensation by essentially 
equalizing steady-state plasma insulin concentrations in obese and lean subjects (Table 2). 
Under non-clamp conditions, the endogenous insulin response in the obese individual is 
augmented in approximate proportion to the fasting hypersecretion (Polonsky et al. 1988); 
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thus, obese subjects may control lipolysis throughout the day by virtue of enhanced p-cell 
function. When the ability of the fi-cell to compensate for the insulin resistance of glucose 
metabolism is impaired, as in the case of diabetes, circulating NEFA are elevated 
throughout the day (Golay et al. 1986~). 
Several studies have shown that body fat distribution plays a role in insulin sensitivity 
independent of total body adiposity (for example, see Coon et al. 1992; Kohrt et al. 1993). 
In the present data, WHR measures, available in a subgroup of 223 subjects rather evenly 
distributed between the lean and obese subgroup, were not significantly related to either 
fasting or post-insulin NEFA concentrations. This could be due to the fact that WHR is a 
poor proxy for intra-abdominal fat deposition, or to an insufficient number of observations 
(or a combination of the two factors). While it has been shown that lipolysis is higher in 
abdominal than peripheral fat depots (Arner, 1995), it should be considered that intra- 
abdominal fat is only a small proportion of total fat mass. Thus, the contribution of 
abdominal fat to total lipolysis may be greatly diluted, and, therefore, only marginally 
related to NEFA concentrations in the peripheral circulation. 
In multivariate analysis, insulin suppression of NEFA levels made a significant, 
independent contribution to insulin action on glucose uptake. This finding reflects the 
operations of Randle’s cycle (Randle et al. 1963), i.e. inhibition of lipolysis leading to 
enhanced glucose uptake. In fact, the regression of our data indicated that an average 84 % 
suppression of plasma NEFA is associated with an increase in glucose uptake of 17 pmoV 
min per kg. At the insulin levels achieved in the present clamp studies, approximately 40 % 
of total glucose uptake is glucose oxidation (Bonadonna et al. 1990). At a circulating 
concentration of 0.6 mmol NEFAA (i.e. the average fasting level in the entire cohort), 
NEFA are oxidized at a rate of approximately 2 pmoYmin per kg (Bonadonna et al. 1990). 
Thus, on average, under the influence of insulin, 6.7 pmol glucose/min per kg (40% of 
17 pmol/min per kg) are oxidized at the cost of sparing 1.7 pmol/min per kg of circulating 
NEFA oxidation. This equivalence is close to the ratio of the energy equivalent of 
palmitate (1 0.0 kJ/pmol) and glucose (2.8 kJ/pmol), implying quantitative replacement of 
NEFA by glucose as fuel for oxidation. Thus, through substrate competition insulin 
suppression of plasma NEFA contributes significantly to whole-body insulin action at any 
age and regardless of obesity or gender. Furthermore, it could be calculated that the 
maximal contribution of NEFA suppression to insulin sensitivity is roughly equivalent to 
half the impact of obesity itself (as the BMI) on insulin sensitivity of glucose metabolism. 
Thus, a strictly metabolic factor is at play to modulate insulin sensitivity in both lean and 
obese subjects. 
In the present study we have clearly demonstrated the relationships between insulin 
resistance, regulation of NEFA concentrations and obesity. Glucose regulation is strongly 
related to NEFA regulation in normal healthy subjects. The mechanisms whereby obesity 
can induce insulin resistance independent of NEFA concentrations have not been 
specifically identified. 
On behalf of EGIR, we wish to thank Groupe Lipha in the person of Dr Christophe Pasik, 
for their generous support of the activities of the Group. 
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